Zeitschriftenartikel zum Thema „H3.3 K27M oncohistone“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "H3.3 K27M oncohistone" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Liu, Ilon, Jiang Li, Daeun Jeong, Olivia A. Hack, McKenzie Shaw, Bernhard Englinger, Byron Avihai et al. „EPCO-06. AGE- AND REGION-SPECIFIC MULTI-OMIC CHARACTERIZATION OF H3-K27M MUTANT DIFFUSE MIDLINE GLIOMA“. Neuro-Oncology 23, Supplement_6 (02.11.2021): vi2. http://dx.doi.org/10.1093/neuonc/noab196.005.
Der volle Inhalt der QuelleLiu, I., L. Jiang, E. Samuelsson, S. Marco Salas, O. Hack, D. Jeong, M. Shaw et al. „JS04.6.A The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location“. Neuro-Oncology 24, Supplement_2 (01.09.2022): ii7. http://dx.doi.org/10.1093/neuonc/noac174.021.
Der volle Inhalt der QuelleLiu, Ilon, Li Jiang, Erik Samuelsson, Sergio Marco Salas, Alexander Beck, Olivia Hack, Daeun Jeong et al. „DIPG-08. THE LANDSCAPE OF TUMOR CELL STATES AND SPATIAL ORGANIZATION IN H3-K27M MUTANT DIFFUSE MIDLINE GLIOMA ACROSS AGE AND LOCATION“. Neuro-Oncology 25, Supplement_1 (01.06.2023): i14. http://dx.doi.org/10.1093/neuonc/noad073.055.
Der volle Inhalt der QuelleHübner, Jens-Martin, Torsten Müller, Dimitris N. Papageorgiou, Monika Mauermann, Jeroen Krijgsveld, Robert B. Russell, David W. Ellison, Stefan M. Pfister, Kristian W. Pajtler und Marcel Kool. „EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma“. Neuro-Oncology 21, Nr. 7 (29.04.2019): 878–89. http://dx.doi.org/10.1093/neuonc/noz058.
Der volle Inhalt der QuelleLiapodimitri, Athanasia, Kayleigh Lunsford, Ashley R. Tetens, Jordyn Craig-Schwartz, Farhad Vesuna, Venu Raman und Michael A. Koldobskiy. „DIPG-64. UNRAVELING H3K27M INTERACTIONS IN DIFFUSE MIDLINE GLIOMA“. Neuro-Oncology 26, Supplement_4 (18.06.2024): 0. http://dx.doi.org/10.1093/neuonc/noae064.117.
Der volle Inhalt der QuelleAndrade, Augusto Faria, Danai Topouza, Michael McNicholas, Eduardo G. Gonzalez Santiago, Antonella De Cola, Arne Gehlhaar, Selin Jessa et al. „TMIC-04. IMMUNE PROFILING OF PEDIATRIC ONCOHISTONE GLIOMAS REVEALS DIVERSE MYELOID POPULATIONS AND TUMOR-PROMOTING BEHAVIORS“. Neuro-Oncology 25, Supplement_5 (01.11.2023): v278. http://dx.doi.org/10.1093/neuonc/noad179.1070.
Der volle Inhalt der QuelleBudd, Kaitlin, Chang-Hyuk Kwon, Lawryn H. Kasper, Christopher Roberts, Jordan Roach, Jennifer Ocasio-Adorno, Jon D. Larson und Suzanne J. Baker. „Abstract IA007: Transforming chromatin: Oncohistone mutations in pediatric high-grade glioma“. Cancer Research 82, Nr. 23_Supplement_2 (01.12.2022): IA007. http://dx.doi.org/10.1158/1538-7445.cancepi22-ia007.
Der volle Inhalt der QuelleKida, Jun-ichiro, Takayuki Tsujioka, Shin-ichiro Suemori, Shuichiro Okamoto, Kanae Sakakibara, Takahiro Yamauchi, Akira Kitanaka, Yumi Tohyama und Kaoru Tohyama. „Malignant Progression of an MDS-Derived Cell Line Serves As an in Vitro Model for the Leukemic Evolution of MDS“. Blood 132, Supplement 1 (29.11.2018): 5501. http://dx.doi.org/10.1182/blood-2018-99-110583.
Der volle Inhalt der QuelleHohm, Annika, Michael Karremann, Gerrit H. Gielen, Torsten Pietsch, Monika Warmuth-Metz, Lindsey A. Vandergrift, Brigitte Bison et al. „Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3 K27M Mutant Diffuse Midline Glioma“. Clinical Neuroradiology 32, Nr. 1 (17.12.2021): 249–58. http://dx.doi.org/10.1007/s00062-021-01120-3.
Der volle Inhalt der QuelleZhang, Peng, Tiantian Han, Yi Lu, Weijie Sun, Wanglong Deng, Guanghua Lu, Didi Guo, Xiaomin Li und Fanfeng Bu. „Molecular characteristics of H3 K27M mutation gliomas in Chinese adults.“ Journal of Clinical Oncology 39, Nr. 15_suppl (20.05.2021): e14018-e14018. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e14018.
Der volle Inhalt der QuelleShema, Efrat. „Abstract PR006: Single-molecule and single-cell epigenetics: Decoding the epigenome for cancer research and diagnostics“. Cancer Research 82, Nr. 23_Supplement_2 (01.12.2022): PR006. http://dx.doi.org/10.1158/1538-7445.cancepi22-pr006.
Der volle Inhalt der QuelleMorita, Shuhei, Masayuki Nitta, Yoshihiro Muragaki, Takashi Komori, Kenta Masui, Takashi Maruyama, Koichi Ichimura et al. „Brainstem pilocytic astrocytoma with H3 K27M mutation: case report“. Journal of Neurosurgery 129, Nr. 3 (September 2018): 593–97. http://dx.doi.org/10.3171/2017.4.jns162443.
Der volle Inhalt der QuelleOdia, Yazmin, Ashley Love Sumrall, Timothy Francis Cloughesy, Phioanh Leia Leia Nghiemphu, Matthew David Hall, Doured Daghistani, Minesh P. Mehta et al. „Single agent activity of ONC201 in non-midline H3 K27M-mutant diffuse gliomas.“ Journal of Clinical Oncology 39, Nr. 15_suppl (20.05.2021): e14037-e14037. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e14037.
Der volle Inhalt der QuelleOdia, Yazmin, Ashley Sumrall, Timothy Cloughesy, Phioanh Nghiemphu, Matthew Hall, Doured Daghistani, Minesh Mehta et al. „CTNI-27. SINGLE AGENT ACTIVITY OF ONC201 IN NON-MIDLINE H3 K27M-MUTANT DIFFUSE GLIOMAS“. Neuro-Oncology 23, Supplement_6 (02.11.2021): vi65. http://dx.doi.org/10.1093/neuonc/noab196.252.
Der volle Inhalt der QuelleGardner, Sharon L., Carl Johannes Koschmann, Rohinton Tarapore, Jeffrey C. Allen, Wafik Tharwat Zaky, Yazmin Odia, Matthew Hall et al. „ONC201 in previously irradiated pediatric H3 K27M-mutant glioma or newly diagnosed DIPG.“ Journal of Clinical Oncology 38, Nr. 15_suppl (20.05.2020): 3619. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3619.
Der volle Inhalt der QuelleKawakibi, Abed Rahman, Rohinton S. Tarapore, Sharon Gardner, Andrew Chi, Sylvia Kurz, Patrick Y. Wen, Isabel Arrillaga-Romany et al. „HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA“. Neuro-Oncology 22, Supplement_3 (01.12.2020): iii347. http://dx.doi.org/10.1093/neuonc/noaa222.305.
Der volle Inhalt der QuelleKawakibi, Abed Rahman, Rohinton Tarapore, Sharon L. Gardner, Sylvia Christine Kurz, Patrick Y. Wen, Isabel Arrillaga-Romany, Tracy Batchelor et al. „Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma.“ Journal of Clinical Oncology 38, Nr. 15_suppl (20.05.2020): 3617. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3617.
Der volle Inhalt der QuelleHall, Matthew D., Yazmin Odia, Joshua E. Allen, Rohinton Tarapore, Ziad Khatib, Toba N. Niazi, Doured Daghistani et al. „First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M–mutant pediatric diffuse intrinsic pontine glioma: a case report“. Journal of Neurosurgery: Pediatrics 23, Nr. 6 (Juni 2019): 719–25. http://dx.doi.org/10.3171/2019.2.peds18480.
Der volle Inhalt der QuelleSchulte, Jessica, Robin Buerki, Sarah Lapointe, Annette Molinaro, Yalan Zhang, Javier Villanueva-Meyer, Arie Perry et al. „PATH-30. CLINICAL AND GENETIC CHARACTERISTICS OF HISTONE H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMAS IN ADULTS“. Neuro-Oncology 22, Supplement_2 (November 2020): ii170—ii171. http://dx.doi.org/10.1093/neuonc/noaa215.711.
Der volle Inhalt der QuelleLiu, Ilon, Li Jiang, Erik R. Samuelsson, Sergio Marco Salas, Alexander Beck, Olivia A. Hack, Daeun Jeong et al. „The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location“. Nature Genetics 54, Nr. 12 (Dezember 2022): 1881–94. http://dx.doi.org/10.1038/s41588-022-01236-3.
Der volle Inhalt der QuelleRahman Kawakibi, Abed, Sharon Gardner, Andrew Chi, Sylvia Kurz, Patrick Wen, Isabel Arrillaga-Romany, Tracy Batchelor et al. „PDCT-12. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA“. Neuro-Oncology 21, Supplement_6 (November 2019): vi186. http://dx.doi.org/10.1093/neuonc/noz175.773.
Der volle Inhalt der QuelleQiu, Tianming, Apisara Chanchotisatien, Zhiyong Qin, Jinsong Wu, Zunguo Du, Xialing Zhang, Fangyuan Gong, Zhenwei Yao und Shuguang Chu. „Imaging characteristics of adult H3 K27M-mutant gliomas“. Journal of Neurosurgery 133, Nr. 6 (Dezember 2020): 1662–70. http://dx.doi.org/10.3171/2019.9.jns191920.
Der volle Inhalt der QuelleChen, Xueling, Ling Zhong, Jianwen Lin und Jian Yu. „A rare case of adult diffuse midline glioma with H3 K27M mutant in the prepontine cistern“. Journal of International Medical Research 49, Nr. 1 (Januar 2021): 030006052098126. http://dx.doi.org/10.1177/0300060520981266.
Der volle Inhalt der QuelleArrillaga-Romany, Isabel, Andrew Lassman, Susan McGovern, Sabine Mueller, L. Burt Nabors, Martin van den Bent, Michael Vogelbaum et al. „RTID-01. ONC108: A RANDOMIZED PHASE 3 STUDY OF ONC201 IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA“. Neuro-Oncology 24, Supplement_7 (01.11.2022): vii249. http://dx.doi.org/10.1093/neuonc/noac209.961.
Der volle Inhalt der QuelleArrillaga-Romany, I., A. Lassman, S. L. McGovern, S. Mueller, L. B. Nabors, M. van den Bent, M. Vogelbaum et al. „P11.46.A ACTION: A RANDOMIZED PHASE 3 STUDY OF DORDAVIPRONE (ONC201) IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA“. Neuro-Oncology 25, Supplement_2 (01.09.2023): ii84. http://dx.doi.org/10.1093/neuonc/noad137.280.
Der volle Inhalt der QuelleArrillaga-Romany, Isabel, Andrew Lassman, Susan McGovern, Sabine Mueller, Louis Burt Nabors, Martin van den Bent, Michael Vogelbaum et al. „TIPS-08 ACTION: A RANDOMIZED PHASE 3 STUDY OF DORDAVIPRONE (ONC201) IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA“. Neuro-Oncology Advances 5, Supplement_3 (01.08.2023): iii35—iii36. http://dx.doi.org/10.1093/noajnl/vdad070.139.
Der volle Inhalt der QuelleDeMasters, B. K., Samuel Guzman und David Ormond. „PATH-18. MORE UNUSUAL FEATURES IN H3 K27M-MUTANT GLIOMAS“. Neuro-Oncology 25, Supplement_5 (01.11.2023): v171. http://dx.doi.org/10.1093/neuonc/noad179.0648.
Der volle Inhalt der QuelleArrillaga-Romany, Isabel, Andrew Lassman, Susan L. McGovern, Sabine Mueller, Louis B. Nabors, Martin van den Bent, Michael Vogelbaum et al. „Abstract CT060: ACTION: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma“. Cancer Research 83, Nr. 8_Supplement (14.04.2023): CT060. http://dx.doi.org/10.1158/1538-7445.am2023-ct060.
Der volle Inhalt der QuelleGardner, Sharon, Rohinton Tarapore, Jeffrey Allen, Wafik Zaky, Yazmin Odia, Matthew Hall, Doured Daghistani et al. „DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG“. Neuro-Oncology 22, Supplement_3 (01.12.2020): iii297. http://dx.doi.org/10.1093/neuonc/noaa222.097.
Der volle Inhalt der QuelleGardner, Sharon L., Jeffrey C. Allen, Wafik Tharwat Zaky, Yazmin Odia, Doured Daghistani, Ziad Khatib, Carl Johannes Koschmann et al. „ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma.“ Journal of Clinical Oncology 37, Nr. 15_suppl (20.05.2019): 10046. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.10046.
Der volle Inhalt der QuelleOdia, Yazmin, Carl Johannes Koschmann, Rohinton Tarapore, Jeffrey Allen, Wafik Tharwat Zaky, Matthew David Hall, Doured Daghistani et al. „Window-of-opportunity study of ONC201 in pediatric patients with diffuse intrinsic pontine glioma (DIPG) and thalamic glioma.“ Journal of Clinical Oncology 40, Nr. 16_suppl (01.06.2022): TPS2082. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps2082.
Der volle Inhalt der QuelleLiu, Ilon, Jiang Li, Erik Samuelsson, Sergio Marco Salas, Alexander Beck, Olivia Hack, Daeun Jeong et al. „EPCO-21. THE SPATIAL ORGANIZATION OF H3-K27M MUTANT DIFFUSE MIDLINE GLIOMA“. Neuro-Oncology 24, Supplement_7 (01.11.2022): vii120. http://dx.doi.org/10.1093/neuonc/noac209.456.
Der volle Inhalt der QuelleJia, Deze, Yi Lu, Xiaomin Li, Tiantian Han, Wanglong Deng, Fanfeng Bu und Guanghua Lu. „Comparison of next-generation sequencing and FISH/IHC for molecular classification in glioma.“ Journal of Clinical Oncology 39, Nr. 15_suppl (20.05.2021): e14021-e14021. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e14021.
Der volle Inhalt der QuelleOdia, Yazmin, Carl Koschmann, Rohinton Tarapore, Jeffrey Allen, Matthew Hall, Doured Daghistani, Ziad Khatib et al. „SYST-07 WINDOW-OF-OPPORTUNITY STUDY OF ONC201 IN PEDIATRIC PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND THALAMIC GLIOMA“. Neuro-Oncology Advances 4, Supplement_1 (01.08.2022): i22. http://dx.doi.org/10.1093/noajnl/vdac078.086.
Der volle Inhalt der QuelleArrillaga-Romany, Isabel, Sylvia Kurz, Ashley Sumrall, Nicholas Butowski, Rebecca Harrison, John DeGroot, Andrew Chi et al. „ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA“. Neuro-Oncology 21, Supplement_6 (November 2019): vi20—vi21. http://dx.doi.org/10.1093/neuonc/noz175.077.
Der volle Inhalt der QuelleKurz, Sylvia Christine, Rohinton Tarapore, Yazmin Odia, Nicholas A. Butowski, Carl Johannes Koschmann, Dolly Aguilera, Tobey J. MacDonald et al. „Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma.“ Journal of Clinical Oncology 38, Nr. 15_suppl (20.05.2020): 2563. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.2563.
Der volle Inhalt der QuelleArrillaga-Romany, Isabel, Sylvia Christine Kurz, Rohinton Tarapore, Ashley Sumrall, Nicholas A. Butowski, Rebecca A. Harrison, John Frederick De Groot et al. „Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.“ Journal of Clinical Oncology 38, Nr. 15_suppl (20.05.2020): 3615. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3615.
Der volle Inhalt der QuelleGessi, Marco, David Capper, Felix Sahm, Kristin Huang, Andreas von Deimling, Stephan Tippelt, Gudrun Fleischhack et al. „Evidence of H3 K27M mutations in posterior fossa ependymomas“. Acta Neuropathologica 132, Nr. 4 (18.08.2016): 635–37. http://dx.doi.org/10.1007/s00401-016-1608-3.
Der volle Inhalt der QuelleSchniederjan, Matthew J., Cahil Potnis, Varshini Vasudevaraja, Catherine D. Moser, Bethany Watson, Matija Snuderl, Tobey MacDonald und Beverly B. Rogers. „DNA Methylation Profiles Are Stable in H3 K27M-Mutant Diffuse Midline Glioma Neurosphere Cell Lines“. Children 11, Nr. 4 (20.04.2024): 492. http://dx.doi.org/10.3390/children11040492.
Der volle Inhalt der QuelleDiaz, Maria, Carlos Eduardo Silva Correia, Andrew Lin, Alexandra Miller und Elena Pentsova. „PATH-04. LEPTOMENINGEAL DISEASE IN PATIENTS WITH HISTONE-MUTANT GLIOMAS“. Neuro-Oncology 23, Supplement_6 (02.11.2021): vi115. http://dx.doi.org/10.1093/neuonc/noab196.457.
Der volle Inhalt der QuellePorter, William, Joshua Sulman, Katie Foot, Ruman Rahman, Richard Grundy, Robert Layfield und Farhana Haque. „HGG-47. Comparative analysis of the Histone H3 mutant protein interactome landscape in paediatric high-grade gliomas“. Neuro-Oncology 24, Supplement_1 (01.06.2022): i71—i72. http://dx.doi.org/10.1093/neuonc/noac079.262.
Der volle Inhalt der QuelleArrillaga-Romany, Isabel, Sylvia Kurz, Rohinton S. Tarapore, Ashley Sumrall, Nicholas Butowski, Rebecca Harrison, John de Groot et al. „CTNI-37. EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA“. Neuro-Oncology 22, Supplement_2 (November 2020): ii50—ii51. http://dx.doi.org/10.1093/neuonc/noaa215.204.
Der volle Inhalt der QuelleHaque, Farhana. „Comparative Analysis of the Histone H3 Mutant Protein Interactome Landscape in Paediatric High-Grade Gliomas“. Neuro-Oncology 24, Supplement_4 (01.10.2022): iv4. http://dx.doi.org/10.1093/neuonc/noac200.016.
Der volle Inhalt der QuelleBalakrishnan, Samantha, Ivan Carabenciov, Michael Ruff, Joon Uhm und Sani Kizilbash. „RARE-37. TREATMENT OF H3K27M MUTANT GLIOMAS WITH PANOBINOSTAT“. Neuro-Oncology 21, Supplement_6 (November 2019): vi229. http://dx.doi.org/10.1093/neuonc/noz175.960.
Der volle Inhalt der QuelleSumrall, Ashley Love, Joanne Xiu, Jennifer M. Eschbacher, Sandeep Mittal, Zoran Gatalica, Manjari K. Pandey, Surasak Phuphanich, Wolfgang Michael Korn, Gregory N. Fuller und Amy B. Heimberger. „Mutations of H3.3 and H3.1 in a large cohort of glioma tumors.“ Journal of Clinical Oncology 37, Nr. 15_suppl (20.05.2019): e13540-e13540. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e13540.
Der volle Inhalt der QuelleArrillaga, Isabel, Sylvia Kurz, Ashley Sumrall, Nicholas A. Butowski, Rebecca A. Harrison, John Frederick De Groot, Nicole A. Shonka et al. „Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.“ Journal of Clinical Oncology 37, Nr. 15_suppl (20.05.2019): 3005. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.3005.
Der volle Inhalt der QuelleAzadi, Amir, Ekokobe Fonkem und Tejas Ranade. „EPID-12. TREATMENT OUTCOMES OF MIDLINE GLIOMAS WITH H3K27 M: OUR BARROW NEUROLOGICAL INSTITUTE EXPERIENCE“. Neuro-Oncology 22, Supplement_2 (November 2020): ii81. http://dx.doi.org/10.1093/neuonc/noaa215.330.
Der volle Inhalt der QuelleGardner, Sharon, Carl Koschmann, Rohinton Tarapore, Jeffrey Allen, Wafik Zaky, Yazmin Odia, Matthew Hall et al. „CTNI-36. SAFETY OF ONC201 ADMINISTERED TWO CONSECUTIVE DAYS PER WEEK IN PEDIATRIC H3 K27M-MUTANT GLIOMA PATIENTS“. Neuro-Oncology 23, Supplement_6 (02.11.2021): vi67. http://dx.doi.org/10.1093/neuonc/noab196.261.
Der volle Inhalt der QuelleDamodharan, Sudarshawn, Montserrat Lara-Velazquez, Brooke Carmen Williamsen, Jeffrey Helgager und Mahua Dey. „Diffuse Intrinsic Pontine Glioma: Molecular Landscape, Evolving Treatment Strategies and Emerging Clinical Trials“. Journal of Personalized Medicine 12, Nr. 5 (20.05.2022): 840. http://dx.doi.org/10.3390/jpm12050840.
Der volle Inhalt der QuelleGrebstad Tune, Benedicte, Heena Sareen, Branka Powter, Smadar Kahana-Edwin, Adam Cooper, Eng-Siew Koh, Cheok S. Lee et al. „From Pediatric to Adult Brain Cancer: Exploring Histone H3 Mutations in Australian Brain Cancer Patients“. Biomedicines 11, Nr. 11 (27.10.2023): 2907. http://dx.doi.org/10.3390/biomedicines11112907.
Der volle Inhalt der Quelle